Clincial Trials match your criteria
-
CHSS: Tricuspid Atresia
Congenital Heart Surgeons’ Society Studies in Congenital Heart Disease: Tricuspid Atresia
-
WARRIOR
Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
-
Ribociclib+Endocrine Therapy as Ad Tx in HR+/HER2Breast Cancer
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
-
Registry for MRIDIAN MRI Based Linear Accelerator Radiation Therapy Treatment Data
Registry for MRIDIAN MRI Based Linear Accelerator Radiation Therapy Treatment Data
-
Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Lung Cancer Patients
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low- Dose Temozolomide in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
-
Phase 2 study of Autologous TIL's for patients with solid tumors
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
-
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
-
MERIT TrialMulti-center ESG Randomized Interventional Trial for the treatment of obesity
Multi-center ESG Randomized Interventional Trial (MERIT-Trial)
-
Head Start 4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
THE “HEAD START 4” PROTOCOL NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS
-
ANTHEM-HFrEF Pivotal Study
AUTONOMIC REGULATION THERAPY TO ENHANCE MYOCARDIAL FUNCTION AND REDUCE PROGRESSION OF HEART FAILURE WITH REDUCED EJECTION FRACTION (ANTHEM-HFrEF) STUDY
